Recent FDA approvals have expanded the indication for semaglutide to include the reduction of major adverse cardiovascular events (MACE), such as heart attack, stroke, and cardiovascular death, in adults with established cardiovascular disease and obesity
The findings were divisive with one expert, Yu-Ming Ni, MD, he would have expected higher good cholesterol (HDL-C) to be associated with lower rates of glaucoma, and higher bad cholesterol (LDL-C) associated with higher rates of glaucoma
While everyone responds differently, there is reason to be cautious about how these medications might impact milk production and overall postpartum recovery
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Future directions Future research directions for the use of GLP-1R agonists in the treatment of pain and headache disorders should focus on conducting human trials to evaluate their efficacy and safety, particularly in individuals with comorbid obesity [60]
That being said, vigilance is warranted particularly in patients with biliary disease, prior pancreatitis, or rapid recent weight loss
